Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by Pareto8020on Oct 02, 2021 11:29am
292 Views
Post# 33957468

October Updated Presentation

October Updated Presentation
https://www.sironabiochem.com/wp-content/uploads/2021/10/SBM-Investor-Presentation-October2021-1.pdf

TFC-1067 & family of skin lighteners
"In discussions with potential partners for global rights"

Hopefully this is the big pharma they were in discussions with last month about their high concentration version of TFC1067.  If they are scooping up the global rights that should have a substantial price tag attached to it.  If I were them I'd just buy the company in its entirety - at a premium (like 10x) to current shareprice. 

TFC-039
Phase I clinical trials completed - Wanbang/Fosun (China)

This is dumbfounding - how the hell have they completed the Phase I studies but Wanbang hasn't given SBM the information as per the contract?  I guess that is what you get when partnering with a firm in China - no cooperation and they've probably already divulged the tech to the State.  They took 7 years+ to do the Phase I now Howard has to nip at their heels and beg for the results - great partners.    



<< Previous
Bullboard Posts
Next >>